




Searching News Database: Onyx Pharmaceuticals
HSMN NewsFeed - 7 Sep 2023
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
HSMN NewsFeed - 13 Jul 2021
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
HSMN NewsFeed - 14 Apr 2015
Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel
Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel
HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
HSMN NewsFeed - 14 Aug 2014
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
HSMN NewsFeed - 14 May 2014
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
HSMN NewsFeed - 16 Apr 2014
Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
HSMN NewsFeed - 6 Feb 2014
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
HSMN NewsFeed - 6 Sep 2013
Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors
Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors
HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 14 Aug 2012
Pharmacyclics(R) Appoints Joshua T. Brumm Executive Vice President of Finance
Pharmacyclics(R) Appoints Joshua T. Brumm Executive Vice President of Finance
HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
HSMN NewsFeed - 9 Jul 2012
Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
HSMN NewsFeed - 7 Feb 2012
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
HSMN NewsFeed - 31 Aug 2011
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
HSMN NewsFeed - 4 Apr 2011
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive Officer
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive Officer
HSMN NewsFeed - 19 Jan 2011
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
HSMN NewsFeed - 5 Jan 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
HSMN NewsFeed - 13 May 2010
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 13 Jan 2009
Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Jennerex Appoints Samantha Miller as Vice President of Corporate Development
HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 14 Jan 2008
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
HSMN NewsFeed - 2 Aug 2007
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed - 13 Jun 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
HSMN NewsFeed - 12 Jun 2006
Onyx Names Laura A. Brege Executive Vice President and Chief Business Officer
Onyx Names Laura A. Brege Executive Vice President and Chief Business Officer
HSMN NewsFeed - 28 Apr 2006
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
HSMN NewsFeed - 26 Apr 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
HSMN NewsFeed - 30 Mar 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Additional items found! 39

Members Archive contains
39 additional stories matching:
Onyx Pharmaceuticals
(Password required)
Onyx Pharmaceuticals
(Password required)